Baricitinib for dermatitis

17th May 2021 by Dr Louise Hudman

Baricitinib for dermatitis

NICE has released a new guideline on the use of Baricitinib in moderate to severe atopic dermatitis. Baricitinib is a Janus kinase (JAK) inhibitor.

As JAK is essential for certain cytokine signalling, by disrupting JAK, you disrupt cytokine signalling and thus disrupt the body’s immune response.

It will be used fourth line (after normal GP treatments, phototherapy and 1 other systemic immunosuppressant).

Read more

No credit card details needed – it takes two minutes.

Join free trial


Already a member? Login to view this content.


Related content

"Since joining NASGP Locum Chambers I have noted a positive change which I feel has made a significant contribution in both my professional and personal life.

LocumDeck's booking system puts me in touch with a large number of surgeries. I work part-time and the software is intricately tailored to facilitate working at my pace and choice.

In addition, I have access to the NASGP Locum Chambers' supporting infrastructure such as the Chambers Manager through whom all my admin work (like generating invoices and pension forms) is organised. In the past this felt like a load. Now I feel that my time is 'freed up' and so I have a better work-life balance. Working with NASGP Locum Chambers has simplified my life."

Dr Smita Iyer, GP, Essex

See the full list of features within our NASGP membership plans